X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2021
Details:
HUMIRA (adalimumab) is the first and only subcutaneous biologic treatment option for pediatric patients from 5 years of age with moderately to severely active ulcerative colitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Gastroenterology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
Approval for adalimumab based on results from the pivotal Phase 3 ENVISION I study showing the higher dosage of HUMIRA induced clinical remission in 60 percent of patients at Week 8 and 45 percent of patients, who responded at Week 8, were in remission at Week 52.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Movantik
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 18, 2021
Details:
The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for pulmonary NTM disease.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
